Research Topics
| Andrew CleggSummaryAffiliation: University of Southampton Country: UK Publications
| Collaborators
|
Detail Information
Publications
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic reviewAndrew Clegg
University of Southampton
Int J Technol Assess Health Care 18:497-507. 2002....
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?J Bryant
Wessex Institute for Health Research and Development, University of Southampton, Biomedical Sciences Building Mailpoint 728, Bassett Crescent East, Southampton SO16 7PX, UK
J Neurol Neurosurg Psychiatry 70:574-9. 2001..To review the clinical effectiveness and costs of a range of disease modifying drugs in multiple sclerosis. Drugs included are azathioprine, cladribine, cyclophosphamide, intravenous immunoglobulin, methotrexate, and mitoxantrone...- Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: a systematic review and economic evaluationJackie Bryant
Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, Boldrewood, Bassett Crescent East, Southampton, UK
Int J Technol Assess Health Care 23:63-70. 2007..The clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators (ICD) for arrhythmias was assessed... - Endocrinology trial design: adverse event reporting in randomised controlled trials of recombinant human GH in GH-deficient adultsJ Bryant
Southampton Health Technology Assessment Centre, Wessex Institute for Health Research and Development, University of Southampton, Bassett Crescent East, UK
J Endocrinol 175:545-52. 2002..Therefore those conducting endocrinology trials in the future need to pay attention to the reporting of withdrawals due to adverse events and specific adverse events... - An economic model of school-based behavioral interventions to prevent sexually transmitted infectionsKeith Cooper
Southampton Health Technology Assessments Centre SHTAC, University of Southampton, Southampton, UK
Int J Technol Assess Health Care 28:407-14. 2012..Behavioral interventions which teach skills to practice safer sex may reduce the incidence of STIs. We evaluated the cost-effectiveness of school-based behavioral interventions in young people... - A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's diseaseJoanna Kirby
Southampton Health Technology Assessments Centre (SHTAC, University of Southampton, Boldrewood, Southampton, UK
Drugs Aging 23:227-40. 2006..However, the effect of memantine on cognitive scores and behaviour and mood outcomes is less clear. Cost-effectiveness is dependent upon assumptions surrounding clinical effect and context-specific cost data... - HTA responses and the classic HTA reportRuairidh Milne
Wessex Institute for Health Research and Development, University of Southampton, Southampton SO16 7PX
J Public Health Med 25:102-6. 2003..Future developments in HTA responses will reflect both the embedding of systematic methods and a growing responsiveness to customer needs... 
Behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19 years: a systematic reviewJoanna Picot
Southampton Health Technology Assessments Centre, University of Southampton, First Floor, Epsilon House, Enterprise Road, University of Southampton Science Park, Southampton, SO16 7NS, UK
Health Educ Res 27:495-512. 2012..Further research could draw on one of the more effective studies reviewed and could explore the effectiveness of 'booster' sessions as young people move from adolescence to young adulthood...- Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessJames Raftery
Wessex Institute for Health R and D, Medical School, University of Southampton, Southampton, UK
Br J Ophthalmol 91:1244-6. 2007..Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD... - Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluationDebbie Hartwell
Southampton Health Technology Assessments Centre, University of Southampton, First Floor Epsilon House, Enterprise Road, Southampton Science Park, Southampton, UK
Cancer Treat Rev 37:242-9. 2011..We performed a systematic review and economic evaluation of topotecan, and consider it here in relation to the NICE end of life criteria... - Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's diseaseColin Green
Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK
Pharmacoeconomics 23:1271-82. 2005..Patients had a mean age of 74 years, a mean disease duration of 1 year and a mean Alzheimer's disease assessment scale-cognitive subscale score of 24...